Shattuck Labs, Inc.
About Shattuck Labs, Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.0M
- Net income
- -$48.8M
- Total assets
- $91.0M
- Market cap
- $351.2M
- Operating margin
- -5150.8%
- Net margin
- -4880.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.0M
- Operating expenses
- $52.5M
- Operating income
- -$51.5M
- Income tax
- $0
- Net income
- -$48.8M
- EPS (basic)
- $-0.70
- EPS (diluted)
- $-0.70
Balance sheet
- Total assets
- $91.0M
- Current assets
- $82.5M
- Total liabilities
- $8.6M
- Current liabilities
- $7.1M
- Shareholders’ equity
- $82.4M
Cash flow
- Operating cash flow
- -$39.9M
- Investing cash flow
- -$7.9M
- Financing cash flow
- $44.6M
- Net cash flow
- -$3.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $351.2M
- EPS (diluted)
- $-0.7
- Shares outstanding
- 90.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 9, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $48.8M in FY2025.
- Revenue declined 97% from FY2021 to FY2025.
- Trading 51% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Shattuck Labs, Inc..
Write a review
News about Shattuck Labs, Inc.
News & sentiment via Polygon.io
